China opportunities

Despite growing medical needs and commercial opportunities, cardiovascular and ophthalmology are still under-invested by Chinese biotech companies. 

Unmet need in Cardiovascular

The 2022 China Cardiovascular Health and Disease Report was released in June 2023 by the National Center for Cardiovascular Disease. The report shows that China's population aging and urbanization processes are currently accelerating, residents' unhealthy lifestyles are becoming more prominent, cardiovascular disease risk factors are becoming more significant, and the incidence of cardiovascular disease is still increasing.

According to the 2021 China Health Statistics Yearbook, CVD will still be the leading cause of death in 2020. According to the data, there are approximately 330 million estimated patients in China suffering from cardiovascular diseases (CVD), including 13 million patients with stroke, 11.39 million with coronary heart disease, and 8.9 million with heart failure. Ischemic heart disease, hemorrhagic stroke, and ischemic stroke are the three major causes of CVD deaths in China. The economic burden of cardiovascular diseases on the population and society has been increasing day by day, and this has become a major public health problem.

Despite the growing unmet need in CVD, pharmaceutical companies have not developed and launched novel treatments at the same rate as other disease areas in China. For example, there have been 54 new molecular entities (NME) approved for cancer between 2015-2020 compared to only 11 NMEs in cardiovascular conditions during the same time. JIXING is committed to bringing innovative cardiovascular therapeutics to China with the goal of improving and saving lives.

Estimated CVD patients
Leading causes of death

Unmet need in Ophthalmology

In China, there is a significant unmet medical need in ophthalmology, often associated with large patient segments. For dry eye disease alone, the patient population is estimated to be over 200 million. Dry eye disease and many other ophthalmic indications are age-related and with China’s aging population, these are important areas of focus.

Overall, new ophthalmic drug approvals in China have lagged compared to some other countries, with only eight new drugs approved in China between 2015-2020 versus 23 drugs in the U.S.. JIXING’s main goal is to develop and deliver innovative ophthalmic therapies to treat diseases with high unmet need in Greater China. As part of our commitment to ensure broad access to treatment for patients and improve diagnosis rates in ophthalmic conditions, we are planning to partner with government initiatives to increase eye examinations as part of the 14th 5-year National Health plan. The ambitious objective is to conduct annual fundus examinations among the broader general population and to meaningfully improve screening and diagnosis of many ophthalmic conditions.

Estimated Dry eye disease patients
Estimated presbyopia patients